# Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT07741565** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 18 (estimated)

## Conditions studied

- HNSCC
- SCC - Squamous Cell Carcinoma
- Oral Cancer

## Interventions

- **DRUG:** Nivolumab-IRDye800

## Key facts

- **NCT ID:** NCT07741565
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2031-09-30
- **Final completion:** 2031-09-30
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741565

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741565, "Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07741565. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*